Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Esperion: Going statins one better

While the blockbuster statin drugs serve to limit the progression of atherosclerosis by lowering LDL cholesterol levels, Esperion Inc. hopes to take this one step further. The company is focusing on HDL metabolism and its role in the Reverse Lipid Transport (RLT) pathway to reverse atherosclerosis.

LDL deposits lipids in the arteries, while HDL acts to remove them. With a portfolio of in-licensed therapeutics and internal genomics-based drug discovery efforts, Esperion is taking two primary approaches in

Read the full 765 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE